Efficacy and Safety of Apatinib Treatment for Patients with Advanced Intrahepatic Cholangiocarcinoma

• Main Authors: Lin G, Wang B, Wu X, Sun T, Chen L, Lu C, Wang N
• Format: Article
• Language: English
• Published: Dove Medical Press 2020-11-01
• Series: Cancer Management and Research
• Subjects: intrahepatic cholangiocarcinoma; apatinib; efficacy; toxicity; progression-free survival
• Online Access: https://www.dovepress.com/efficacy-and-safety-of-apatinib-treatment-for-patients-with-advanced-i-peer-reviewed-article-CMAR
• ISSN: 1179-1322

Guohe Lin,1,* Bicheng Wang,2,* Xiuwei Wu,1 Tong Sun,1 Lili Chen,1 Canliang Lu,3 Nianfei Wang1 1Department of Oncology, The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230601, People’s Republic of China; 2Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, People’s Republic of China; 3Department of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui 230022, People’s Republic of China*These authors contributed equally to this workCorrespondence: Nianfei WangDepartment of Oncology, The Second Affiliated Hospital of Anhui Medical University, Furong Road No. 678, Hefei, Anhui 230601, People’s Republic of ChinaEmail [e-mail] LuDepartment of Hepatopancreatobiliary Surgery, Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Jixi Avenue No. 218, Hefei, Anhui 230022, People’s Republic of ChinaEmail [e-mail]: Effective treatment options for intrahepatic cholangiocarcinoma (ICC) are limited. This study was intended to explore the efficacy and safety of apatinib in advanced ICC with lymph node metastasis or distant metastasis.Patients and Methods: The efficacy and toxicity of apatinib were evaluated in patients with ICC between November 2017 and March 2020 at the Second Affiliated Hospital of Anhui Medical University. Survival analysis was estimated using Kaplan–Meier method.Results: Ten patients with advanced ICC were enrolled. The median progression-free survival (PFS) was 3.0 months (95% CI: 1.450– 4.550). No patient achieved a complete response (CR). One patient gained partial response (PR), and 6 patients had stable disease (SD). The objective response rate (ORR) was 10%, and the disease control rate (DCR) was 70%. The common treatment-related adverse events were hypertension (20%), proteinuria (30%), hand and foot syndrome (10%) or emesis (10%). No grade 3/4 toxicities occurred. Toxicities were mild and tolerable.Conclusion: Apatinib is potentially an effective treatment option with tolerable toxicities for patients with advanced ICC.Keywords: intrahepatic cholangiocarcinoma, apatinib, efficacy, toxicity, progression-free survival